ArticlePeerJ2025
Integrative bioinformatics analysis identifies C1orf198 as a novel prognostic biomarker in colorectal cancer.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related mortality, necessitating the identification of novel prognostic biomarkers to improve patient management. In this study, we integrated bioinformatics analyses and experimental validation to explore the role of C1orf198 in CRC. Data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) revealed significantly upregulated C1orf198 mRNA in CRC tissues compared to normal counterparts, confirmed by immunohistochemistry (IHC) in clinical samples. High C1orf198 expression correlated with advanced tumor stages (T, N, M) and poor survival outcomes, including shorter overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI). Functional enrichment analyses highlighted involvement in extracellular matrix organization, cell adhesion, and oncogenic signaling pathways such as PI3K-AKT and focal adhesion. Immune infiltration analysis showed positive correlations with stromal/immune scores and M2 macrophage infiltration, linking C1orf198 to tumor microenvironment (TME) remodeling. Notably, C1orf198 was strongly associated with cytokines CXCL12 and receptors CXCR5, which mirrored its immune cell correlations. Collectively, our findings identify C1orf198 as a potential prognostic biomarker in CRC, implicating its role in TME modulation and oncogenic progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.